BidaskClub downgraded shares of Dynavax Technologies (NASDAQ:DVAX) from a buy rating to a hold rating in a report published on Wednesday.
Several other brokerages have also commented on DVAX. William Blair restated an outperform rating and issued a $30.00 price target on shares of Dynavax Technologies in a research note on Wednesday, August 9th. Royal Bank Of Canada reiterated an outperform rating and set a $28.00 price objective (up previously from $26.00) on shares of Dynavax Technologies in a research note on Monday, September 25th. Cowen reiterated a buy rating and set a $30.00 price objective on shares of Dynavax Technologies in a research note on Friday, November 3rd. ValuEngine lowered shares of Dynavax Technologies from a hold rating to a sell rating in a research note on Friday, December 1st. Finally, Cantor Fitzgerald raised their price objective on shares of Dynavax Technologies from $24.00 to $25.00 and gave the company an overweight rating in a research note on Thursday, November 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. Dynavax Technologies has a consensus rating of Buy and a consensus price target of $25.17.
Shares of Dynavax Technologies (DVAX) traded down $0.10 during trading hours on Wednesday, hitting $17.30. 1,138,800 shares of the company’s stock traded hands, compared to its average volume of 1,871,026. Dynavax Technologies has a 12 month low of $3.70 and a 12 month high of $24.45.
Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.53) by $0.15. Dynavax Technologies had a negative net margin of 1,177.60% and a negative return on equity of 65.97%. The company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.28 million. During the same quarter last year, the business earned ($0.90) earnings per share. Dynavax Technologies’s revenue was down 68.8% compared to the same quarter last year. equities research analysts forecast that Dynavax Technologies will post -1.72 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Dynavax Technologies by 474.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,120 shares of the biopharmaceutical company’s stock valued at $153,000 after acquiring an additional 5,880 shares during the period. Cubist Systematic Strategies LLC increased its stake in shares of Dynavax Technologies by 54.5% during the second quarter. Cubist Systematic Strategies LLC now owns 10,493 shares of the biopharmaceutical company’s stock valued at $101,000 after acquiring an additional 3,700 shares during the period. Patriot Financial Group Insurance Agency LLC boosted its holdings in Dynavax Technologies by 16.5% during the second quarter. Patriot Financial Group Insurance Agency LLC now owns 12,000 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 1,700 shares in the last quarter. Legal & General Group Plc boosted its holdings in Dynavax Technologies by 18.5% during the second quarter. Legal & General Group Plc now owns 12,501 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 1,950 shares in the last quarter. Finally, Wall Street Access Asset Management LLC bought a new stake in Dynavax Technologies during the second quarter worth approximately $124,000. Institutional investors and hedge funds own 70.61% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Dynavax Technologies (DVAX) Downgraded by BidaskClub to “Hold”” was first reported by Stock Observer and is the property of of Stock Observer. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.thestockobserver.com/2017/12/07/dynavax-technologies-dvax-downgraded-by-bidaskclub-to-hold.html.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.